Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose

Journal of Pain and Symptom Management

Volumn 27, Issue 4, 2004, Pages 352-359

  Mercadante, Sebastiano ^a   Villari, Patrizia ^a   Ferrera, Patrizia ^a   Bianchi, Mauro ^b   Casuccio, Alessandra ^c  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breakthrough pain; Cancer pain; Intravenous morphine

Indexed keywords

MORPHINE;

AGE; ANALGESIA; ARTICLE; BLOOD SAMPLING; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAUSEA; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VOMITING;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PALLIATIVE CARE;

EID: 1642619135     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2003.09.006     Document Type: Article

References (20)

1. Portenoy R.K., Hagen N.A. Breakthrough pain: definition, prevalence and characteristics. Pain. 41:1990;273-281.
2. Caraceni A., Portenoy R.K. An international survey of cancer pain characteristics and syndromes. Pain. 82:1999;263-274.
3. Mercadante S., Radbruch L., Caraceni A., et al. Episodic (breakthrough) pain. Cancer. 94:2002;832-839.
4. Mercadante S., Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 24:1998;425-432.
5. Mercadante S., Maddaloni S., Roccella S., Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 50:1992;151-155.
6. Bruera E., Schoeller T., Wenk R., et al. A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage. 10:1995;348-355.
7. Portenoy R.K., Payne D., Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 81:1999;129-134.
8. Coluzzi P., Schwartzberg L., Conroy J., et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain. 91:2001;123-130.
9. Mercadante S., Villari P., Ferrera P., et al. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer. 95:2002;203-208.
10. Christie J., Simmonds M., Patt R., et al. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 16:1998;3238-3245.
11. Farrar J., Cleary J., Rauck R., et al. Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 90:1998;611-616.
12. Portenoy R.K., Payne R., Coluzzi P., et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 79:1999;303-312.
13. Hanks G.W., De Conno F., Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 84:2001;587-593.
14. Jacox A., Carr D.B., Payne R., et al. Management of cancer pain, clinical practice guidelines No.9. AHCPR Publication No.94-0592. March 1994;Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Helath Services, Rockville, MD.
15. Glare P., Walsh D., Groh E., Nelson K.A. The efficacy and side effects of continuous infusion intravenous morphine (CIVM) for pain and symptoms due to advanced cancer. Am J Hosp Care. 19:2002;343-350.
16. Mercadante S., Villari P., Ferrera P. A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer. 11:2003;114-119.
17. Farrar J., Portenoy R.K., Berlin J., et al. Defining the clinically important difference in pain outcome measures. Pain. 88:2000;287-294.
18. Lichtor J., Sevarino F., Joshi G., et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg. 89:1999;732-738.
19. Collins S.L., Faura C.C., Moore R.A., McQuay H.J. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage. 16:1998;388-402.
20. Enting R., Oldenmenger W., van der Rijt C., et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer. 94:2002;3049-3056.